Project Grant R44CA302204
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $1.1M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Golden, CO, USA
Similar Awards
- The National Institutes of Health National Cancer Institute awarded Pulmera, Inc., $1.131690 million on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop advanced three-dimensional imaging technology to improve diagnostic accuracy during bronchoscopic lung biopsy for suspected lung cancer. Bronchoscopic lung biopsy currently achieves diagnostic accuracy of 60–82%, substantially lower than transthoracic needle aspiration, which benefits from...
- The National Cancer Institute awarded Eleuthra Photonics, Inc. $399,268 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for Phase I Small Business Innovation Research (SBIR) development of nonlinear optics label-free microscopy technology to improve prostate cancer diagnosis from fresh needle biopsy specimens. The recipient will optimize the TetraQuant system for high-resolution imaging of fresh prostate needle biopsies by fabricating a custom...
- Federal Grant Award Summary Cereus Diagnostics Corp. received a $764,448 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 1, 2025, with completion targeted for July 31, 2028. The company is developing LUNG-FAST (Fragment Analysis, SNP, and Translocations), a rapid polymerase chain reaction (PCR)-based diagnostic test designed to detect clinically actionable lung cancer mutations including EGFR, KRAS, ALK,...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $140,400 on July 17, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop multimodal, interpretable artificial intelligence models that integrate digital pathology images and tumor genomic data to improve precision cancer diagnosis and treatment selection. The award funds a two-phase K99/R00 career development grant. During the K99 phase, the recipient will study multimodal self-supervised...
- Federal Grant Award Summary Darwin Biosciences, Inc. received a $399,998 Project Grant award dated July 17, 2025, from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an innovative point-of-need lung cancer screening device for low-resource settings. The company is adapting its existing handheld diagnostic platform—previously developed under a $12 million Department of Defense contract for pathogen detection—to identify lung cancer...
- The National Cancer Institute awarded Chrononai, LLC $399,997 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and commercialize a foundation AI model for live cell phenotyping in cancer research. The recipient will develop a deep learning–based foundation model that integrates cell contour tracking with a time-series transformer architecture to extract dynamic morphodynamic features from live-cell movies and incorporate spatial...
- The National Cancer Institute awarded the University of Washington $405,244 on August 13, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and optimize immunopixelseq, a cost-effective spatial immunosequencing platform for precision immuno-oncology research. Immunopixelseq uses 0.6-micrometer-resolution polony gel stamping to produce low-cost arrays compatible with standard Illumina short-read sequencing, enabling spatial co-profiling of whole-tissue...
- Federal Project Grant Award Summary Award Details: The National Cancer Institute (NCI) awarded O2M Technologies LLC a $1,164,814 Project Grant on September 19, 2025, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) for research extending through August 31, 2027. The award supports the development of advanced imaging methods in pulse electron paramagnetic resonance (EPR) to enable precise partial oxygen pressure (pO2) measurements for cancer diagnosis and treatment...
- The National Cancer Institute awarded $400,000 to Zeest Bio Inc. on September 15, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a novel liver-specific positron emission tomography tracer for improved detection of metastatic tumors and assessment of liver function and biliary tract pathology. The recipient will complete preclinical testing and investigational new drug-enabling studies in preparation for first-in-human clinical trials. Current imaging...
- The National Cancer Institute awarded the Institute For Systems Biology $555,592 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop AI-driven infrastructure for integrating and analyzing cancer datasets and identifying cancer risk factors. The recipient will construct a multi-modal, harmonized resource for the tumor microenvironment featuring an AI-powered spatial search tool. Using spatial datasets from the Human Tumor Atlas Network (HTAN), the...